The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.



Latest Headlines

Latest Headlines

Novartis and Roche now have France eyeing competition issues

Efforts to steer doctors away from off-label use of cancer drug Avastin in favor of the pricier Lucentis for treating sight issues have gotten Swiss drugmakers Roche and Novartis fined by the anticompetition authority in Italy, where prosecutors are also taking a look, and now French regulators say they are in the midst of a probe of their own.

Novartis's new Basel campus reflects Vasella's (now out-of-fashion) style

The careful, buttoned-down style favored by Novartis' top execs in Basel has been getting a makeover--at least on the architectural front.

Novartis orphan drug Jakavi nabs 'blockbuster' forecasts on new data

Novartis may have another cancer blockbuster on its hands. New Phase III data on Jakavi (ruxolitinib) has Wall Street analysts predicting that it will easily pass the $1 billion mark.

Novartis sees start of $2B dermatology opportunity with new EU Xolair approval

On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives--the first such product cleared there for patients who don't respond to antihistamines alone.

A Phase III win puts Incyte's cancer drug in line for blockbuster status

Incyte CEO Hervé Hoppenot has been telling anyone who'll listen that his biotech is undervalued and underestimated, and now, with promising late-stage results for its lead drug in a rare blood cancer, the company has a shot at blockbuster sales alongside partner Novartis.

Novartis nabs a new anti-hives use for Xolair in the EU

As the company points out, it's the only product cleared for patients whose chronic spontaneous urticaria haven't responded to antihistamines.

Italian prosecutors jump into Roche, Novartis case with fraud probe

After their antitrust-fighting colleagues levied $251 million in fines against Swiss drugmakers Roche and Novartis on allegations that they colluded to protect sales of their eye drug, Italian prosecutors are now investigating possible market manipulation and fraud, according to Reuters.

Novartis' 'breakthrough' muscle drug is worth $4B, if you ask MorphoSys

Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.

Italy levies eye-opening antitrust fines against Roche, Novartis over Lucentis

Doctors have been prescribing Roche's cancer drug Avastin off-label to treat some of the same vision problems as its eye drug, Lucentis. Now, Italy's antitrust authority has fined Roche and marketing partner Novartis,  accusing them of colluding to push doctors toward the pricier option--claims the pair denies.

The top 10 pharma companies by 2013 revenue

The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....